Amgen Inc
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen NEUPOGEN (filgrastim by Year
NEUPOGEN (filgrastim — Neutropenia, legacy standalone disclosure) — Rest of World (ROW) product sales ($M) ($M)
Amgen NEUPOGEN (filgrastim: $57M in FY2022, down 14.9% from a year earlier. No newer figure appears in the documents we track.
Where the FY2022 figure comes from
“|| NEUPOGEN — ROW | 57 | (15) | % | 67 | (17) | % | 81”
Source: Form 10-K (amgn-20221231.htm, filed 2023-02-09) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | NEUPOGEN (filgrastim — Neutropenia, legacy standalone disclosure) — Rest of World (ROW) product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2022 | Dec 31, 2022 | 57 | -14.9% | Form 10-K (amgn-20221231.htm, filed 2023-02-09) ↗ |
| FY2021 | Dec 31, 2021 | 67 | -17.3% | Form 10-K (amgn-20211231.htm, filed 2022-02-16) ↗ |
| FY2020 | Dec 31, 2020 | 81 | -5.8% | Form 10-K (amgn-20201231.htm, filed 2021-02-09) ↗ |
| FY2019 | Dec 31, 2019 | 86 | -39.4% | Form 10-K (amgn-12312019x10kq42019.htm, filed 2020-02-12) ↗ |
| FY2018 | Dec 31, 2018 | 142 | -21.1% | Form 10-K (amgn-12312018x10kq42018.htm, filed 2019-02-13) ↗ |
| FY2017 | Dec 31, 2017 | 180 | – | Form 10-K (amgn-12312017x10k.htm, filed 2018-02-13) ↗ |
Cite this data
StockData. (2026). Amgen NEUPOGEN (filgrastim ($M), annual FY2017–FY2022 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-neupogen-row
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.